Analyst Julien Ouaddour of Bank of America Securities maintained a Buy rating on Alcon, retaining the price target of CHF89.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Julien Ouaddour has given his Buy rating due to a combination of factors, primarily focusing on Alcon’s strategic acquisition of Staar Surgical. This acquisition is expected to enhance Alcon’s refractive surgery portfolio by complementing its existing offerings, particularly for individuals with severe myopia. The transaction is anticipated to be accretive by the second year, suggesting potential financial benefits for Alcon.
Despite the risks associated with Staar Surgical’s significant revenue exposure to China, Julien believes that Alcon can mitigate these risks by leveraging its commercial capabilities to diversify geographically. Additionally, Alcon’s appealing growth and margin profile projected towards the end of 2025 into 2026 further supports the Buy rating, indicating a positive outlook for the company’s financial performance.
In another report released today, UBS also maintained a Buy rating on the stock with a CHF100.00 price target.